Results 211 to 220 of about 32,827 (233)

MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells

Cell Biochemistry and Biophysics, 2020
We aimed to understand the molecular mechanism underlying the incidence of Oxaliplatin resistance in colorectal cancer. The Oxaliplatin-resistant (OR) HT29 colorectal cell line was established by long-term exposure to Oxaliplatin. Cell viability and proliferation were determined by the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide and ...
Zhicheng Zhao, Guojing Zhang, Weidong Li
openaire   +2 more sources

Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab

Clinical Cancer Research, 2007
AbstractPurpose: To establish whether cetuximab, a chimeric IgG1 antibody targeting epidermal growth factor receptor, has the potential to restore responsiveness to oxaliplatin in preclinical cancer models, as has been shown with irinotecan in irinotecan refractory metastatic colorectal cancer patients.Experimental Design: The effects of cetuximab and ...
Marie, Prewett, Dhanvanthri S, Deevi, Rajiv, Bassi, Fan, Fan, Lee M, Ellis, Daniel J, Hicklin, James R, Tonra   +6 more
openaire   +2 more sources

The involvement of Aurora‐A and p53 in oxaliplatin‐resistant colon cancer cells

Journal of Cellular Biochemistry, 2023
AbstractResistance to chemotherapy is the deadlock in cancer treatment. In this study, we used wild‐type LOVO (LOVOWT), a human colon cancer cell line, and the oxaliplatin‐resistant sub‐clone LOVOOR cells to investigate the molecular mechanisms of the development of drug resistance in colon cancer.
Mei‐Chih Chen, Bing‐Ze Yang, Wei‐Wen Kuo, Shih‐Hsin Wu, Tso‐Fu Wang, Yu‐Lan Yeh, Ming‐Cheng Chen, Chih‐Yang Huang   +7 more
openaire   +2 more sources

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

British Journal of Cancer, 2007
[[abstract]]To identify mechanisms underlying oxaliplatin resistance, a subline of the human gastric adenocarcinoma TSGH cell line, S3, was made resistant to oxaliplatin by continuous selection against increasing drug concentrations.
L -T Chen, J-Y Chang, Chen C-C
exaly   +2 more sources

Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance [PDF]

, 2023
内容の要約
openaire  

Role of Dicer in regulating oxaliplatin resistance of colon cancer cells

Biochemical and Biophysical Research Communications, 2018
Colorectal cancer (CRC) is a major health problem due to its high mortality rate. The incidence of CRC is increasing in young individuals. Oxaliplatin (OXA) is an approved third-generation drug and is used for first-line chemotherapy in CRC. Although current standard chemotherapy improves the overall survival of CRC patients, an increasing number of ...
Hui-Huang Lai, Li-Jyuan Lin, Liang-Yi Hung, Pai-Sheng Chen   +3 more
openaire   +2 more sources

Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells

Cancer Letters, 1996
Elevation of glutathione (GSH) is commonly observed in cellular resistance to a number of anticancer agents. Most frequently reported change in GSH metabolism that is associated with the elevated GSH levels is increased mRNA expression and activity of gamma-glutamyl cysteine synthetase (gamma GCS), the first enzyme of the GSH biosynthetic pathway.
Z, el-akawi, M, Abu-hadid, R, Perez, J, Glavy, J, Zdanowicz, P J, Creaven, L, Pendyala   +6 more
openaire   +2 more sources

Cellular Resistance to Oxaliplatin and Drug Accumulation Defects

2009
Platinum drugs are employed in a wide range of solid tumors, and represent the mainstay of the first-line therapy of ovarian carcinoma. Although cisplatin has shown efficacy in the treatment of different types of tumors including ovarian carcinoma, resistance to treatment is a major limitation.
Laura Gatti, Paola Perego
openaire   +1 more source

TGFB1-mediated autophagy facilitates oxaliplatin resistance in stomach adenocarcinoma

Biochemistry and Cell Biology
Increasing evidence has indicated that transforming growth factor beta 1 (TGFB1) is engaged in tumorigenesis and progression. Nevertheless, the underlying role and mechanism of TGFB1 in stomach adenocarcinoma (STAD) chemotherapy remains unknown. TGFB1 levels in various types of cancers were first analyzed by the TCGA database.
Qihua Xu, Sheng Hu, Qilin Zhang, Huijun Zhang, Jianfeng Liu, Ying Zhou, Tianning Tian, Bingling Liao   +7 more
openaire   +2 more sources

Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer

Molecular Therapy, 2021
Haiyang Zhang, Xinyi Wang, Kegan Zhu
exaly